海正药业：9月16日召开董事会会议

Group 1 - The core point of the article is that Haizheng Pharmaceutical announced a strategic partnership with Shenzhen Aixin Dawei Pharmaceutical Technology Co., Ltd. through a product exclusive licensing agreement [1] - The company's revenue composition for the year 2024 is as follows: pharmaceutical production accounts for 58.46%, drug sales for 39.29%, other industries for 1.94%, other businesses for 0.23%, and CMO/CDMO/CRO business for 0.08% [1] - As of the report, Haizheng Pharmaceutical has a market capitalization of 12.5 billion yuan [1]